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Sir,
We read the interesting article by Forward et al (2004) on the
clinical and endocrine data for goserelin plus anastrozole in
premenopausal women with advanced breast cancer. The authors
presented interesting data regarding serum gonadotropin (FSH
and LH) levels and androgen (testosterone, DHEAS and andros-
tenedione) levels in 13 patients treated with the GnRH agonist,
goserelin, plus the selective oestrogen receptor modulator,
tamoxifen, followed by goserelin plus the aromatase inhibitor,
anastrozole. The authors found that goserelin and tamoxifen led to
a 90% fall in FSH levels down to 1.0IU/L at 6 months (Po0.001).
Once the therapy was changed to goserelin and anastrozole, there
was a significant rise in the mean FSH level to 7.8IU/l at 12 months
(Po0.0001). Introduction of goserelin and tamoxifen resulted in
an 89% reduction in mean LH levels (pretreatment vs 6 month-
s¼19.9 vs 0.3IU/l; P¼0.01), but with substitution of tamoxifen by
anastrozole, no significant change in LH levels occurred.
With regard to androgen levels, the authors found a significant
fall in testosterone and androstenedione, but not DHEAS, levels in
association with substitution of tamoxifen by anastrozole.
In their explanation for these observations, the authors
suggested that the rise in FSH was due to release of a negative
feedback as a result of further reduction in oestradiol levels upon
the introduction of an aromatase inhibitor, or a rebound
phenomenon from coming off tamoxifen. Regarding the significant
decline in androgen levels (testosterone and androstenedione),
contrary to what is expected (a rise due to potential substrate
accumulation secondary to inhibition of the aromatase enzyme),
the authors provided little in the way of discussion.
We would like to propose a possible mechanism for the
endocrine changes found in this study. Regarding the differential
changes in gonadotropins (rise in FSH levels while LH levels
remained suppressed) with substitution of tamoxifen by the
aromatase inhibitor, anastrozole, we believe that involvement of
the activin/inhibin/follistatin system could explain these changes.
Accumulating evidence suggests that oestrogen can modulate
gonadotropin production through a direct effect on pituitary cells,
independent of GnRH. This effect is thought to be mediated
through the activin/inhibin/follistatin system (DePaolo, 1997; Nett
et al, 2002; Welt et al, 2002; McNeilly et al, 2003). Activins are
produced by a wide variety of tissues including the pituitary gland,
and are specifically by gonadotropes (Roberts et al, 1989). Activins
stimulate synthesis of FSH by a direct action on the gonadotropes
(Mason et al, 1989). Follistatin, also produced by the pituitary
gland, is an activin-binding protein and may decrease FSH
synthesis by sequestering activin (Mather et al, 1993). Oestrogen
was found to selectively suppress FSH production but not LH
through an increase in follistatin/inhibin and a decrease in activin,
independent of GnRH (Shupnik and Rosenzweig, 1991; DiGregorio
and Nett, 1995; Baratta et al, 2001), mainly through activin
suppression (Baratta et al, 2001).
Testosterone has been found to have the opposite effect of
oestrogen on pituitary FSH (but not LH) production, that is, an
increase in FSH by the gonadotropes. This effect was found to be
mediated through locally produced activins (Burger et al, 2004).
Potentially, testosterone may accumulate at the tissue level as a
result of aromatase inhibition even in the absence of measurable
changes in the serum. Such locally accumulated testosterone could
exert a stimulatory effect on FSH production by the anterior
pituitary through an activin-mediated effect. The reason why a
more suppressive effect on FSH production occurred with the
antioestrogen tamoxifen is probably related to its selective
oestrogen receptor modulation effect, known to exert antioestro-
genic effects at the level of the hypothalamus, but oestrogenic
effects at the level of the pituitary gland (Gonzalez et al, 2000).
The significant decline in testosterone and androstenedione, but
not DHEAS, in the face of aromatase inhibition is much harder to
rationalise. It is possible that inhibition of oestrogen locally in the
hypothalamus and pituitary by the aromatase inhibitor, together with
GnRH receptor downregulation by goserelin, resulted in profound
combined suppression of LH levels, especially at the level of
bioactivity, which is not totally reflected in the immunoassay results.
It is important to mention that the evidence presented above
came mainly from animal studies. However, if we can extrapolate
from the available animal data, it is pertinent here to point out
another potential mechanism for aromatase inhibitors to enhance
the efficacy of controlled ovarian hyperstimulation (COH) proto-
cols, as we have recently reported (Mitwally and Casper, 2002,
2003, 2004). The ability of the aromatase inhibitors to increase
endogenous FSH production by the anterior pituitary, even with
pituitary GnRH receptor downregulation (as in the present
publication by Forward et al), is an exciting approach to improve
the outcome of ovarian stimulation particularly in poor responders
in in vitro fertilisation protocols. We believe this area of aromatase
inhibitor use warrants further investigation. *Correspondence: Dr MP Diamond; E-mail: mdiamond@med.wayne.edu
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